PAS
CLSD

PKS Advisory Services’s Clearside Biomedical CLSD Stock Holding History

PKS Advisory Services’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,633
Closed -$19.6K – 249
2025
Q2 		$19.6K Hold
1,633
– – ﹤0.01% 260
2025
Q1 		$22.5K Hold
1,633
– – 0.01% 242
2024
Q4 		$23.3K Buy
+1,633
New +$26.9K 0.01% 245

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $6.15B AUM 22.62% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PKS Advisory Services's CLSD Position: Q3 2025 in Review

PKS Advisory Services sold out of Clearside Biomedical (CLSD) in Q3 2025, closing a stake of 1,633 shares — an estimated $19.6K sold.

PKS Advisory Services first reported a position in CLSD in Q4 2024 and held it in 3 quarters. The position peaked at $23.3K in Q4 2024. 26 funds tracked by Wall St. Rank hold CLSD as of Q3 2025.

  • PKS Advisory Services reported no remaining Clearside Biomedical position as of Q3 2025 after selling out during the quarter.
  • PKS Advisory Services sold 1,633 Clearside Biomedical shares in Q3 2025, an estimated $19.6K.
  • PKS Advisory Services first reported a position in Clearside Biomedical in Q4 2024 and held it in 3 quarters.
  • PKS Advisory Services's Clearside Biomedical position peaked at $23.3K in Q4 2024.
  • 26 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2025.

Based on PKS Advisory Services's 13F filing for Q3 2025, filed 12 Nov 2025.